Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1691-1698

  Park, See Hyoung ^a   Lee, Jung Han ^b   Berek, Jonathan S ^a   Hu, Mickey C T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hanyang University   (South Korea)

Author keywords

Apoptosis; Auranofin; Bax; Bim; Cancer; Caspase; Forkhead; FOXO; I B kinase; p53; Tumor suppression

Indexed keywords

AURANOFIN; BIM PROTEIN; CASPASE 3; I KAPPA B KINASE BETA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TRANSCRIPTION FACTOR FKHRL1; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMING UNIT; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; UPREGULATION; CELL NUCLEUS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AURANOFIN; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907451634     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2579     Document Type: Article

References (42)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Banerjee S and Kaye SB: New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 19: 961-968, 2013.
3. Shigetomi H, Higashiura Y, Kajihara H and Kobayashi H: Targeted molecular therapies for ovarian cancer: an update and future perspectives. Oncol Rep 28: 395-408, 2012.
4. Snyder RM, Mirabelli CK and Crooke SJ: The cellular pharmacology of auranofin. Semin Arthritis Rheum 17: 71-80, 1987. (Pubitemid 17135785)
5. Madeira JM, Gibson DL, Kean WF and Klegeris A: The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 20: 297-306, 2012.
6. Columbo M, Galeone D, Guidi G, Kagey-Sobotka A, Lichtenstein LM, Pettit GR and Marone G: Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin. Biochem Pharmacol 39: 285-2891, 1990.
7. Rigobello MP, Scutari G, Boscolo R and Bindoli A: Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharmacol 136: 1162-1168, 2002. (Pubitemid 34970068)
8. Jeon KI, Jeong JY and Jue DM: Thiol-reactive metal compounds inhibit NF-κB activation by blocking IκB kinase. J Immunol 164: 5981-5989, 2000.
9. Kim IS, Jin JY, Lee IH and Park SJ: Auranofin induces apoptosis and when combined with retinoid acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol 142: 749-755, 2004. (Pubitemid 38969669)
10. Park SJ and Kim IS: The role of p38 MAPK activation for auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol 146: 506-513, 2005.
11. Tsai WB, Chung YM, Zou Y, Park SH, Xu Z, Nakayama K, Lin SH and Hu MC: Inhibition of FOXO3 tumor suppressor function by βTrCP1 through ubiquitin-mediated degradation in a tumor mouse model. PLoS One 5: e11171, 2010.
12. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R and Hung MC: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225-237, 2004. (Pubitemid 38496242)
13. Katoh M and Katoh M: Human FOX gene family. Int J Oncol 25: 1495-1500 2004.
14. Alvarez B, Martinez AC, Burgering BM and Carrera AC: Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413: 744-747, 2001. (Pubitemid 33009953)
15. Furukawa-Hibi Y, Kobayashi Y, Chen C and Motoyama N: FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 7: 752-760, 2005. (Pubitemid 40563215)
16. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999. (Pubitemid 29165088)
17. Sunters A, Fernández de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC and Lam EW: FOXO3 transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278: 49795-49805, 2003. (Pubitemid 37548813)
18. Fu Z and Tindall DJ: FOXOs, cancer and regulation of apoptosis. Oncogene 27: 2312-2319, 2008. (Pubitemid 351501782)
19. Chung YM, Park SH, Tsai WB, Wang SY, Ikeda MA, Berek JS, Chen DJ and Hu MC: FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat Commun 3: 1000, 2012.
20. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiStefano PS, Chiang LW and Greenberg ME: DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296: 530-534, 2002. (Pubitemid 34408672)
21. Tsai WB, Chung YM, Takahashi Y, Xu Z and Hu MC: Functional interaction between FOXO3 and ATM regulates DNA damage response. Nat Cell Biol 10: 460-467, 2008.
22. Yang J-Y, Xia W and Hu MC: Induction of FOXO3a and Bim expression in response to ionizing radiation. Int J Oncol 29: 643-648, 2006.
23. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, Burgering BM, Coombes RC and Lam EW: Paclitaxel-induced nuclear translocation of FOXO3 in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 66: 212-220, 2006. (Pubitemid 43166027)
24. Nemoto S, Fergusson MM and Finkel T: Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306: 2105-2108, 2004. (Pubitemid 40007664)
25. Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425, 2005. (Pubitemid 41637981)
26. Seoane J, Le HV, Shen L, Anderson SA and Massagué J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211-223, 2004. (Pubitemid 38496241)
27. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH and DePinho RA: FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309-323, 2007. (Pubitemid 46123514)
28. Miyamoto K, Araki KY, Naka K, Arai F, Takubo K, Yamazaki S, Matsuoka S, Miyamoto T, Ito K, Ohmura M, Chen C, Hosokawa K, Nakauchi H, Nakayama K, Nakayama KI, Harada M, Motoyama N, Suda T and Hirao A: FOXO3 is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1: 101-112, 2007. (Pubitemid 46865800)
29. Huang H and Tindall DJ: FOXO factors: a matter of life and death. Future Oncol 2: 83-89, 2006.
30. Hu MC and Hung MC: Role of IkappaB kinase in tumorigenesis. Future Oncol 1: 67-78, 2005.
31. Eijkelenboom A and Burgering BM: FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol 14: 83-97, 2013.
32. Lu M, Zhao Y, Xu F, Wang Y, Xiang J and Chen D: The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer. Med Oncol 29: 3409-3915, 2012.
33. Fei M, Zhao Y, Wang Y, Lu M, Cheng C, Huang X, Zhang D, Lu J, He S and Shen A: Low expression of Foxo3a is associated with poor prognostic in ovarian cancer patients. Cancer Invest 27: 52-59, 2009.
34. Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO and Powe DG: FOXO3a nuclear localization is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res Treat 129: 11-21, 2011.
35. Nicholson DW: Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6: 1028-1042, 1999.
36. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994. (Pubitemid 24300618)
37. Kumari SR, Mendoza-Alvarez H and Alvarez-Gonzalez R: Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment. Cancer Res 58: 5075-5078, 1998. (Pubitemid 28521164)
38. Carvajal LA and Manfredi JJ: Another fork in the road - life or death decisions by the tumour suppressor p53. EMBO Rep 14: 414-421, 2013.
39. Yoshida K and Miki Y: The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci 101: 831-835, 2010.
40. Das S, Boswell SA, Aaronson SA and Lee SW: P53 promoter selection: choosing between life and death. Cell Cycle 7: 154-157, 2008. (Pubitemid 351366513)
41. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW and Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14: 195-208, 2007.
42. Chong CR and Sullivan DJ Jr: New uses for old drugs. Nature 448: 645-646, 2007. (Pubitemid 47236844)